Chicago, USA – March 26, 2026
GE HealthCare announced a leading industrial role in the €50.5 million COMPASS consortium, one of the largest EU-funded initiatives under the Innovative Health Initiative (IHI), aimed at advancing cardio-oncology care through artificial intelligence, advanced imaging, and biomarker-driven precision medicine. The five-year program brings together more than 60 partners across Europe to address the growing burden of cardiovascular complications in cancer patients, a major emerging challenge as survival rates improve.
AI-Powered Innovation in Cardio-Oncology
The COMPASS consortium is focused on leveraging AI-enabled predictive models, real-world data, and advanced diagnostic tools to enhance early detection and prediction of cardiotoxicity associated with cancer therapies. As the use of chemotherapy, radiotherapy, and targeted oncology treatments continues to expand, so does the risk of cardiovascular side effects, making early identification and intervention critical.
The initiative will integrate multi-omics biomarker discovery, molecular imaging, and wearable health data to create highly accurate predictive systems that support clinicians in making informed decisions and delivering personalized patient care.
Addressing a Critical Clinical Challenge
Advertisement
Cardiovascular disease has become a significant complication in oncology, now recognized as the second leading cause of death among cancer survivors, accounting for up to 10% of mortality globally. This growing issue is driven by both the long-term effects of cancer therapies and pre-existing cardiovascular conditions in patients. However, current clinical approaches remain limited due to insufficient understanding of cardiotoxic mechanisms, lack of reliable biomarkers, and absence of standardized preventive strategies.
The COMPASS initiative aims to bridge these gaps by developing evidence-based, integrated care pathways that connect oncology and cardiology, enabling safer continuation of cancer treatment while minimizing cardiovascular risks.
Integrated Care Pathways and Future Impact
A key objective of the consortium is to establish end-to-end, patient-centered clinical pathways that support early risk prediction, continuous monitoring, and long-term management of cardiovascular health in cancer patients. By fostering multidisciplinary collaboration between clinicians, researchers, and industry stakeholders, the program seeks to translate innovation into routine clinical practice across Europe.
The integration of AI-driven decision support systems with clinical workflows is expected to improve treatment outcomes, reduce complications, and enhance overall patient survival. Backed by the Horizon Europe framework, this initiative underscores the increasing role of digital health, precision medicine, and collaborative research in shaping the future of healthcare systems globally.
Source: GE HealthCare press release
